Related Experiment Video
Updated: Jul 2, 2025
05:28
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
Published on: May 5, 2020
2.3K
One-year outcomes after prostate artery embolization versus laser enucleation: A network meta-analysis
Ansh Bhatia1,2, Joao Gabriel Porto3, Aneesha Maini4
1Department of Interventional Radiology, Miller School of Medicine University of Miami Miami Florida USA.
BJUI Compass
|February 19, 2024
Summary
Holmium laser enucleation (HoLEP) and prostate artery embolization (PAE) show comparable short-term outcomes for benign prostatic hyperplasia. While HoLEP offers better initial flow rates, PAE has fewer serious adverse events.
Area of Science:
- Urology
- Minimally Invasive Surgery
- Interventional Radiology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition requiring treatment.
- Holmium laser enucleation (HoLEP) is a size-independent BPH treatment.
- Prostate artery embolization (PAE) is an emerging alternative for moderate to large BPH.
Purpose of the Study:
- To compare the early post-operative and short-term efficacy of PAE and HoLEP for BPH treatment.
- To evaluate key outcome metrics including symptom scores, urinary flow, and adverse events.
Main Methods:
- A network meta-analysis of studies from PubMed, Cochrane Library, and EMBASE.
- Included analysis of international prostate symptom score (IPSS), quality of life (QOL), post-void residual urine (PVR), maximal uroflow rate (Qmax), and serious adverse events (SAE).
- Utilized random effects models to calculate weighted mean differences (WMD) and odds ratios (OR).
Main Results:
- At 3 months, no significant differences in IPSS, QOL, or PVR improvement between PAE and HoLEP.
- HoLEP showed superior Qmax improvement at 3 months.
- At 1 year, no significant differences in IPSS, QOL, PVR, or Qmax improvement were observed.
- PAE was associated with a lower incidence of serious adverse events (SAE) compared to HoLEP.
Conclusions:
- HoLEP demonstrated superiority in Qmax improvement at 3 months.
- No significant differences in key efficacy parameters were found at 1-year follow-up.
- PAE offers a potential advantage with fewer serious adverse events, but long-term durability requires further investigation.
